azilsartan medoxomil

an azilsartan prodrug and angiotensin II type 1 receptor blocker

Also Known As:

TAK 491; TAK-491; TAK491; 1H-benzimidazole-7-carboxylic acid, 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Networked: 67 relevant articles (8 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        azilsartan medoxomil: 67
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - azilsartan medoxomil: 67

Experts

1.	White, William B: 11 articles (11/2018 - 03/2011)
2.	Kupfer, Stuart: 11 articles (10/2018 - 03/2011)
3.	Bakris, George L: 10 articles (11/2018 - 03/2011)
4.	Lloyd, Eric: 9 articles (11/2018 - 08/2012)
5.	Weber, Michael A: 9 articles (11/2018 - 03/2011)
6.	Sica, Domenic: 7 articles (01/2018 - 03/2011)
7.	Roberts, Andrew: 6 articles (07/2018 - 08/2012)
8.	Handley, Alison: 6 articles (09/2017 - 07/2011)
9.	Cushman, William C: 5 articles (11/2018 - 08/2012)
10.	Juhasz, Attila: 5 articles (10/2018 - 04/2016)

Related Diseases

1.	Hypertension (High Blood Pressure) 09/01/2019 - "This study will summarize all the available data to provide reliable evidence of the value of different doses of azilsartan medoxomil for the treatment of hypertension. " 09/01/2019 - "Randomized controlled trials reporting efficacy and safety of different doses of azilsartan medoxomil on hypertension will be included if they compared 1 dose of azilsartan medoxomil with another dose of azilsartan medoxomil or with a placebo. " 09/01/2019 - "This study will perform a network meta-analysis to assess the efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension. " 07/01/2017 - "The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour mean systolic blood pressure (BP). " 12/15/2021 - "High efficacy and acceptability of the drug was associated with a beneficial effect on renal function, which allows to consider azilsartan medoxomil as the drug of choice for the treatment of hypertension in patients with concomitant metabolic disorders. "
2.	Insulin Resistance 07/01/2013 - "The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle." 07/01/2013 - "The effectiveness of azilsartan medoxomil (AZIL-M), a novel imidazole-based ARB, to facilitate metabolic improvements in conditions of angiotensin II (Ang II)-associated insulin resistance is currently unknown. " 11/01/2011 - "In a 2-week study in SHRs, azilsartan medoxomil showed more stable antihypertensive effects than olmesartan medoxomil and improved the glucose infusion rate, an indicator of insulin sensitivity, more potently (≥ 10 times) than olmesartan medoxomil. "
3.	Overweight 01/01/2021 - "An international multicenter observational non-interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT)." 01/01/2021 - "Thus, azilsartan medoxomil demonstrated a good safety profile and provided effective blood pressure control for overweight or obese patients with hypertension in real clinical practice." 12/15/2021 - "To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders. " 12/15/2021 - "[The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders]."
4.	Essential Hypertension 01/01/2016 - "This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg). " 01/01/2016 - "Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study." 09/01/2012 - "In adults with essential hypertension, azilsartan medoxomil 20, 40 or 80 mg effectively reduced BP over a 24-hour period with once-daily administration in three major, randomized, controlled trials in which the primary endpoints were changes from baseline in 24-hour mean systolic BP (SBP) at week 6 (two trials) or week 24, assessed by ambulatory BP monitoring (ABPM). " 10/01/2018 - "Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg and 24-hour SBP 140-175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL-M) monotherapy for 4 weeks. " 01/01/2018 - "Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo (n = 65), azilsartan medoxomil (AZL-M) 40 mg (n = 132), or AZL-M 80 mg (n = 131). "
5.	Type 2 Diabetes Mellitus (MODY) 01/01/2022 - "This phase 4 study evaluated the efficacy and safety of azilsartan medoxomil (AZL-M) in patients with essential hypertension and type 2 diabetes mellitus (T2DM) in Hong Kong, Taiwan, and Thailand. " 01/01/2022 - "A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia." 01/01/2016 - "Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). " 04/01/2016 - "Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes."

Related Drugs and Biologics

1.	Chlorthalidone (Chlortalidone)
2.	Antihypertensive Agents (Antihypertensives)
3.	Angiotensin Receptor Antagonists
4.	Olmesartan Medoxomil (Votum)
5.	Indicators and Reagents (Reagents)
6.	Glucose (Dextrose)
7.	Thiazides
8.	Diuretics
9.	Angiotensin II
10.	Hydrochlorothiazide (Esidrix)

Related Therapies and Procedures

1.	Therapeutics